Prognostic and predictive markers of response to treatment in patients with locally advanced unresectable and metastatic pancreatic adenocarcinoma treated with gemcitabine/nab-paclitaxel: Results of a retrospective analysis
| Autor: | Lidia Vázquez Tuñas, Guillermo Alfonso Quintero Aldana, Paula Gonzalez Villarroel, Manuel Valladares Ayerbes, Mercedes Salgado Fernández, Ana Fernández Montes, Mónica Jorge Fernández, Juan de la Cámara Gómez |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Male
0301 basic medicine Oncology medicine.medical_specialty Paclitaxel metastatic pancreatic adenocarcinoma Disease Adenocarcinoma Deoxycytidine lcsh:RC254-282 03 medical and health sciences nab-paclitaxel 0302 clinical medicine Albumins Internal medicine Antineoplastic Combined Chemotherapy Protocols Biomarkers Tumor medicine Humans Radiology Nuclear Medicine and imaging Neoplasm Metastasis Survival analysis Aged Retrospective Studies business.industry Proportional hazards model predictive markers Retrospective cohort study General Medicine Middle Aged Metastatic Pancreatic Adenocarcinoma Prognosis lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Survival Analysis Response to treatment Gemcitabine Pancreatic Neoplasms Regimen 030104 developmental biology 030220 oncology & carcinogenesis locally advanced unresectable pancreatic cancer Female business medicine.drug |
| Zdroj: | Journal of Cancer Research and Therapeutics, Vol 13, Iss 2, Pp 240-245 (2017) |
| ISSN: | 1998-4138 0973-1482 |
| Popis: | Background: Recent studies support the use of gemcitabine and nab-paclitaxel in adults with locally advanced unresectable or metastatic pancreatic adenocarcinoma although insufficient data are available on prognostic and predictive markers of response to treatment. Objective: The objective of this study is to identify treatment response markers in patients with locally advanced unresectable or metastatic pancreatic adenocarcinoma. Materials and Methods: This is an observational, retrospective, and multicenter study. Sociodemographic, clinical, and therapeutic data were collected. Cox regression models were applied to determine associations. Results: In total, 39 patients were included; 23.1% presented locally advanced pancreatic cancer and 76.9% metastatic disease. They received a mean of 6 ± 3 treatment cycles; 59% required dose reduction, 59% treatment delay, and 20.5% switched to a biweekly regimen. The overall response rate was 23% and the disease control rate was 81%. Median progression-free survival was 9 months and median overall survival (OS) was 15 months. A higher neutrophil/lymphocyte ratio (NLR) was significantly associated with lower OS. We reported Grades 1–4 nonhematological and hematological toxicities. Conclusion: NLR is a useful prognostic factor for OS in patients with locally advanced unresectable or metastatic pancreatic adenocarcinoma treated with gemcitabine and nab-paclitaxel. Moreover, we suggest that a biweekly regimen is an option for certain groups of patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|